From CBC News:
Hearing a human say blood-thinner doses are correct may be reassuring, but an automated system can be equally effective for some, a new study suggests.
In Monday's online issue of the Canadian Medical Association Journal, researchers concluded that an automated voice response system reduced the workload by 33 per cent and was almost as effective as a phone call from a human.
About five per cent of seniors take oral anticoagulants such as warfarin for blood clotting disorders. Patients need to take regular blood tests to make sure they're taking the right dose — too little doesn't work, and too much can cause serious bleeding problems including a deadly form of stroke.
The dose has to be individualized and monitored closely, said study author Dr. Alan Forster, a patient safety expert with the Ottawa Hospital Research Institute and the University of Ottawa.
The study was designed to test whether computer algorithms can predict the right dose better than a human.
"The interactive voice response system was effective in communicating complex information as 77.8 per cent of messages were successfully delivered and did not require input from staff," Forster and his coauthors wrote. ...more
Showing posts with label anticoagulation. Show all posts
Showing posts with label anticoagulation. Show all posts
Tuesday, April 28, 2009
Monday, December 10, 2007
J&J, Bayer Pill Caused Fewer Clots Than Sanofi Drug in Study
From Bloomberg:
Bayer AG and Johnson & Johnson's experimental blood thinner led to fewer clots and deaths in patients after hip surgery than a widely used therapy sold by Sanofi-Aventis SA, a study found.
About 1.1 percent of patients had serious blood clots or died on the Bayer and J&J pill, rivaroxaban, compared with 3.7 percent of those taking Sanofi's injected medicine, Lovenox, according to research reported today at the American Society of Hematology meeting in Atlanta. Both drugs had similar rates of bleeding, a side effect of anti-clotting medications.
Rivaroxaban may help J&J and Bayer take market share from the injectable Lovenox, Sanofi's best-seller with $3.5 billion in sales last year. Bayer, Germany's largest drugmaker, asked European regulators to allow sale of the drug under the brand name Xarelto in October, and has projected peak sales of $2.9 billion. J&J, of New Brunswick, New Jersey, has said it will seek U.S. marketing approval in the second half of 2008. ...more
Bayer AG and Johnson & Johnson's experimental blood thinner led to fewer clots and deaths in patients after hip surgery than a widely used therapy sold by Sanofi-Aventis SA, a study found.
About 1.1 percent of patients had serious blood clots or died on the Bayer and J&J pill, rivaroxaban, compared with 3.7 percent of those taking Sanofi's injected medicine, Lovenox, according to research reported today at the American Society of Hematology meeting in Atlanta. Both drugs had similar rates of bleeding, a side effect of anti-clotting medications.
Rivaroxaban may help J&J and Bayer take market share from the injectable Lovenox, Sanofi's best-seller with $3.5 billion in sales last year. Bayer, Germany's largest drugmaker, asked European regulators to allow sale of the drug under the brand name Xarelto in October, and has projected peak sales of $2.9 billion. J&J, of New Brunswick, New Jersey, has said it will seek U.S. marketing approval in the second half of 2008. ...more
Subscribe to:
Posts (Atom)